The biologics market will attain considerable traction in the following years, thanks to the surging investments from major companies, surge in cases of chronic disorders, and the patent exclusivity of major biologic drugs coming to an end. Soaring demand and acceptability of biologics for advanced therapies will also add to the market strength. Biologic drugs facilitate effective treatment of a number of chronic disorders, most notably autoimmune diseases and cancer. This enables the top pharmaceutical companies such as Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, GlaxoSmithKline (GSK), and Novartis, to make large-scale investments in these drugs, resulting in massive business growth.